El Mundo on MSN
Europe Hooks on Chinese Drugs: Journey to the Starting Point of the New Silk Road of Medicines
The dependency on Asia grows to supply its pharmaceutical industry and ensure the provision of essential medicines. Among the ...
The deal marks Lilly’s first in the M&A arena in 2026 as the company diversifies its pipeline beyond obesity drugs.
Let's consider two such companies in the biotech industry: Axsome Therapeutics (NASDAQ: AXSM) and Exelixis (NASDAQ: EXEL).
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback